Observational studyFrontiers in public health2025
Medicine affordability and access in India: lessons from generic-branded price variation under the Jan Aushadhi Scheme.
Observational study in Frontiers in public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Gaps in access and trust: essential medicine availability, affordability, and barriers to generic medicine use.Public health action · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: High out-of-pocket expenditure (OOPE) on medicines continues to be a major driver of health-related financial hardship in India. The Jan Aushadhi Scheme (JAS), launched by the Government of India, seeks to improve affordability and access to essential medicines through generic substitution. However, systematic evidence on its pricing dynamics, affordability, and equity implications remains limited. Methods: We conducted an observational analysis of 696 branded formulations for Eye and Ear, Nose, and Throat (ENT) conditions, comparing their prices with Jan Aushadhi generics listed in the Pharmaceuticals and Medical Devices Bureau of India (PMBI). Data were drawn from the Current Index of Medical Specialties (CIMS, 2021) and PMBI catalogs. Cost ratios and price variation percentages were calculated, alongside affordability assessment using the WHO/HAI one-day wage benchmark. Correlation and regression models assessed the relationship between brand proliferation and price dispersion. Supplementary analyses included chronic disease medicines (diabetes, hypertension, and insulin), distribution trends of Jan Aushadhi Kendras (2018-2022), and global benchmarking using WHO indicators. Results: Branded formulations exhibited wide cost variation, with correlation analysis showing that greater brand numbers were associated with higher-not lower-price dispersion. While most JAS medicines met the WHO affordability threshold, chronic therapies such as glaucoma drugs remained financially burdensome for low-income households. Supplementary analyses demonstrated that dosage form, packaging, and storage requirements contribute to persistent price gaps. Geographic analysis revealed strong growth in Kendras (3,200 in 2018 to 9,000 in 2022), but significant inequities persisted, with large states such as Uttar Pradesh and Bihar showing low per-capita availability. Global benchmarking highlighted India's paradox: despite being a global leader in generic production, domestic uptake of generics remains far below comparator countries. Conclusion: The Jan Aushadhi Scheme has made measurable progress in improving medicine affordability, but inequities in access, persistent price variation, and limited uptake constrain its full potential. Strengthening regulatory oversight, improving geographic distribution, and addressing physician and patient perceptions of generics are essential to maximize policy impact. Future research should apply quasi-experimental methods and integrate patient perception data to better capture the affordability-access-adherence pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.